Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 3, 1999, Pages 1533-1538

  Tanahashi, Masayuki ^a   Hara, Sunao ^a   Yoshida, Makoto ^a   Suzuki Kusaba, Mizue ^a   Hisa, Hiroaki ^a   Satoh, Susumu ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAMIDE; CYCLIC AMP; INDOMETACIN; PHOSPHODIESTERASE IV; ROLIPRAM; SODIUM;

ANIMAL EXPERIMENT; ARTICLE; CYCLIC AMP URINE LEVEL; DOG; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GLOMERULUS FILTRATION RATE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; SODIUM URINE LEVEL; URINE FLOW RATE;

ANESTHESIA, GENERAL; ANIMALS; BLOOD PRESSURE; CYCLIC AMP; DIURESIS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; INDOMETHACIN; KIDNEY; MALE; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; QUINOLONES; RENAL CIRCULATION; ROLIPRAM; SODIUM; VASCULAR RESISTANCE;

EID: 0033060749     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ando Y and Asano Y (1995) Luminal prostaglandin E2 modulates sodium and water transport in rabbit cortical collecting ducts. Am J Physiol 268:F1093-F1101.
2. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748.
3. Beavo JA and Reifsnyder DH (1990) Primary sequence of cyclic nucleotide phospho-diesterase isozymes and the design of selective inhibitors. Trends Pharmacol 11:150-155.
4. Begany DP, Carcillo JA, Herzer WA, Mi Z and Jackson ED (1996) Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J Pharmacol Exp Ther 278:37-41.
5. Chini CCS, Chini EN, Williams JM, Matouovic K and Dousa TP (1994) Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV. Kidney Int 46:28-36.
6. Davidson WD and Sackner MA (1963) Simplification of the enthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62:351-356.
7. Disanto ME and Heaslip RJ (1995) Rolipram inhibition of phosphodiesterase-4 activation. Eur J Pharmacol 290:169-172.
8. Hidaka H and Endo T (1984) Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase: Basic and potential clinical applications. Adv Cyclic Nucleotide Res 16:245-259.
9. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T and Saitoh Y (1979) Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 211:26-30.
10. Higashio T, Abe Y, Miyazaki M and Yamamoto K (1980) Renal effects of 8-substituted derivatives of adenoaine 3′,5′-cyclic monophosphate in dogs. Experientia 36:234-236.
11. Hisa H, Takahashi K and Satoh S (1984) Evidence for prostaglandin-independent mechanisms in renin release mediated by alpha adrenoceptors during renal nerve stimulation in anesthetized dogs. J Pharmacol Exp Ther 229:547-550.
12. Jackson EK, Mi Z, Carcillo JA, Gillespie DG and Dubey RK (1997) Phosphodiesterase in the rat renal vasculature. J Cardiovasc Pharmacol 30:798-801.
13. Kariya T and Dage RC (1988) Tissue distribution and selective inhibition of subtypes of high affinity cAMP phosphodiesterase. Biochem Pharmacol 37:3267-3270.
14. Lindgren S and Andersson KE (1991) Effects of selective phosphodiesterase inhibitors on isolated coronary, lung and renal arteries from man and rat. Acta Physiol Scand 142:77-82.
15. Masuoka H, Ito M, Nakano T, Naka M and Tanaka T (1990) Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart. J Cardiovasc Pharmacol 15:302-307.
16. Nicholson CD, Challiss RAJ and Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19-27.
17. +-ATPase activity is lacking in Dahl salt-sensitive rats. Hypertension 21: 767-771.
18. Noland TD, Caeter CE, Jacobson HR and Breyer MD (1992) PGE2 regulates cAMP production in cultured rabbit CCD cells: Evidence for dual inhibitory mechanisms. Am J Physiol 263:C1208-C1215.
19. Okahara T, Abe Y and Yamamoto K (1977) Effects of dibutyryl cyclic AMP and propranolol on renin secretion in dogs. Proc Soc Exp Biol Med 156:213-218.
20. Oliw E, Änggard E and Fredholm BB (1977) Effect of indomethacin on the renal actions of theophylline. Eur J Pharmacol 43:9-16.
21. Reinhart RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC and Bondy CA (1995) Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterase. J Clin Invest 95:1528-1538.
22. Robinson JWL and Mirkovitch V (1980) The effect of cAMP on dog renal function. Experientia 36:1304-1306.
23. Tamaki T, Hasui K, Shoji T, Aki Y, Kiyomoto H, Iwao H and Abe Y (1991) Forskolin preferentially dilates the afferent arteriole in the canine kidney. Jpn J Pharmacol 56:161-164.
24. Thompson WJ (1991) Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmacol Ther 51:13-33.
25. Torphy TJ, Livi GP, Balcarek JM, White JR, Chilton FH and Undem BJ (1992) Therapeutic potential of isozyme-selective phosphodiesterase inhibitor in the treatment of asthma. Adv Second Messenger Phosphoprotein Res 25:289-305.
26. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ and Dousa TP (1996) Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymee types III and IV. J Clin Invest 88:262-270.
27. + exchanger in rabbit kidney brush-border membranes. Am J Physiol 252:F19-F25.
28. Yamaki M, Mcintyre S, Rassier ME, Schwartz JH and Dousa TP (1992) Cyclic 3′,5′-nucleotide diesterases in dynamics of cAMP and cGMP in rat collecting duct cells. Am J Physiol 262:F957-F964.